Ferritin & ALC Predict PFS in Myeloma Bispecific Antibody Therapy | Tarek Mouhieddine, MD #IMS25

Ferritin & ALC Predict PFS in Myeloma Bispecific Antibody Therapy | Tarek Mouhieddine, MD #IMS25
Blood Test Reveals Myeloma Genetics Using Cell-Free DNA | Dory Abelman, PhdD(c) #IMS25
How MRD Status Is Being Used to Guide Myeloma Treatment Decisions | Ben Derman MD #IMS25
Lymphocyte Count Used to Predict Delayed Neurotoxicity in Myeloma CAR-T | Hitomi Hosoya MD #ims25
Shared Decision-Making Matters When Choosing Myeloma Treatment | Martine Elias,Myeloma Canada #IMS25
MRD Relapse vs Biochemical Relapse -Restarting Myeloma Therapy | Fredrik Schjesvold, MD, PhD #IMS25